Life Sciences

GSK announces plans to increase transparency of clinical research

Pharma Compliance Alert, April 1, 2009

GlaxoSmithKline (GSK) will disclose payments to U.S. healthcare professionals and their institutions to conduct clinical trials beginning in 2010, according to the company’s 2008 Corporate Responsibility Report.

In the future, GSK plans to disclose payments for other types of research and to healthcare professionals and institutions outside the United States. The company also plans to expand publication of clinical trials on its Clinical Study Register to include all meta-analyses, observational studies, and studies of terminated compounds.

Read more about GSK’s plans to increase transparency.

Most Popular